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ABSTRACT 
 
Background 
Depression has adverse effects on health outcomes and the quality of end-of-life care among 
cancer patients. However, overly aggressive EOL care can result in high costs and may not be 
consistent with patient preferences or linked to better health. As such, there is rising interest in 
identifying the associations between depression and care quality for cancer patients. This study 
investigates whether depression is associated with EOL care intensity among elderly individuals 
with cancer. 
Methods 
Utilizing the Surveillance, Epidemiology, and End Results-Medicare linked database, we 
identified decedents aged 66 years or older either with pre-cancer depression, post-cancer 
depression, or no depression at all. All participants were diagnosed with cancer from 2004-2011 
and died within 3 years as a result of cancer. Using hierarchical generalized linear models, we 
determined the associations of pre- and post-cancer depression on EOL care intensity, adjusting 
for sociodemographic and clinical characteristics. 
Results 
Our sample consisted of 84,947 Medicare beneficiaries, of whom 5,072 (6%) had pre-cancer 
depression and 6,677 (7.9%) had post-cancer depression. Compared to participants without 
depression, those with pre-cancer depression were significantly less likely to have repeated 
hospitalizations (adjusted odds ratio [AOR] = 0.91, 95% confidence interval [CI] = 0.83-0.99) or 
emergency department visits (AOR = 0.89, 95% CI = 0.83-0.94), experience in-hospital death 
(AOR = 0.83, 95% CI = 0.77-0.89), and receive intensive care unit services (AOR = 0.86, 95% 
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CI = 0.79-0.93) or late chemotherapy (AOR = 0.83, 95% CI = 0.70-0.99), and more likely to use 
hospice care (AOR = 1.20, 95% CI = 1.12-1.28). Participants with post-cancer depression had 
similar care intensity patterns as those with pre-cancer depression, but were insignificantly more 
likely to have repeat hospitalizations than those without depression (AOR = 1.04, 95% CI = 
0.97-1.12). 
Conclusions 
Participants with pre- or post-cancer depression were less likely to receive aggressive EOL care 
than those without depression. Our findings suggest understanding the mechanisms that lead to 
these patterns may enhance EOL care quality for patients with cancer. Accurate screening and 
treatment for depressed patients in addition to earlier communication and initiation of hospice for 
all cancer patients can help promote palliative care. 
 
Keywords: cancer, depression, end-of-life care, intensity, oncology 
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Introduction 
 There is rising interest in identifying the associations between depression and end-of-life 
(EOL) care intensity for patients with cancer.1, 2 Previous research shows that cancer patients 
have an increased risk of depression compared to the general population.3-7 The prevalence of 
depression is high in patients with terminal illnesses like cancer,8, 9 where estimates vary that 
15% to 50% of patients with cancer will experience depressive symptoms.7, 9-12 Because 
depression is among one of the leading causes of disability globally, it has major implications for 
health outcomes and quality of life among affected individuals.9 These repercussions consist of 
adverse effects on functional status, health-related quality of life, health care use, and medical 
costs.13-15 Several studies indicate co-occurring depression and cancer may impact the morbidity 
of patients such that those with depression and cancer are less likely to adhere to treatment 
regimens and more likely to have other comorbidities and prolonged hospital stays compared to 
patients without depression; these factors can lead to increased health care utilization, high 
expenditures, and more aggressive EOL cancer care.1, 3, 14, 16  
Case in point, EOL care constitutes a disproportionate amount of Medicare costs, 
accounting for more than one-fourth of the spending on the elderly in the last year of life.17, 18 In 
addition, overly aggressive EOL care may not be consistent with patient wishes or associated 
with better health and quality of life.19-21 While studies have examined the effects of depression 
on cancer patients in terms of health care utilization and expenditures, there is a dearth of 
literature investigating the associations of pre- or post-cancer depression with EOL care intensity 
among adults with cancer. Available research examining depression and EOL care among those 
with cancer is limited in both study scope and sample size3, 22-24 or unclear in its diagnostic 
criteria for depression.16 That is, it is not clear if depression preceded or followed the cancer 
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diagnosis. One study found that in adult cancer patients (≥21 years), depression is associated 
with higher health care utilization and expenditures, but the window of time for a depression 
diagnosis was not defined.16 Three studies investigating elderly patients with a certain type of 
cancer, either breast, colorectal, or pancreatic, determined that pre-cancer depression is 
associated with a decrease in EOL care intensity.3, 22, 24 Conversely, a study examining the 
prevalence and cumulative expenditures of post-cancer depression on patients with prostate 
cancer (>65 years) determined depression during the treatment phase was correlated with 
significant health resource utilization, expenses, and mortality.23 The evidence so far is 
inconclusive. Potential explanations include: 1) the timeframe in which depression occurs, either 
prior to or after a cancer diagnosis, may affect participants’ EOL cancer care differently, and 2) 
there is also a possibility that different types of cancer are influencing these effects. This issue is 
important to investigate on a more comprehensive scale, as EOL care costs are exorbitant. 
To our knowledge, previous studies have not concomitantly evaluated differences in the 
quality and intensity of EOL care with cancer patients’ psychological well-being across the 
mental health spectrum, such as depression both prior to and after cancer diagnosis. It is probable 
elderly patients with cancer may be less likely to seek care when ill as a result of depression,22 
but it is not known whether they have significantly different patterns of health care utilization 
and costs compared to those without depression. We hypothesize that patients with pre- or post-
cancer depression will be less likely to receive aggressive EOL cancer care than those without 
depression. To address this knowledge gap, we investigated whether depression is associated 
with differences in EOL care intensity patterns over time in a population-based cohort of 
Medicare beneficiaries who had died from cancer, incorporating a comprehensive range of 
cancer types and criteria for the different depression groups. We then analyzed the associations 
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between depression and EOL care intensity patterns after controlling for sociodemographic, 
health status, and market variables. Understanding how mental illness may be correlated with 
EOL care for cancer patients can help expand current knowledge on the underlying mechanism 
leading to these differences and has potential implications for policy and action. Evidence of a 
relationship between a pre- or post-cancer diagnosis of depression and subsequent EOL care 
quality for adults with terminal cancers might also identify a select group for whom mental 
health services may be most needed or support earlier communication and initiation of hospice 
care, among other palliative care options, for patients.  
 
Methods 
Data source and study design 
 For this retrospective cohort analysis, we utilized the Surveillance, Epidemiology, and 
End Results (SEER)-Medicare database, a unique population-based data source that links 
Medicare enrollment and claims to cancer registries from the time of a beneficiary’s Medicare 
eligibility until date of death.25 To date, the SEER cancer registries encompass approximately 
30% of the United States population, collecting information on cancer incidence and survival.25 
We used SEER data to identify patient sociodemographic and cancer tumor characteristics for 
our sample. We used Medicare inpatient and outpatient claims to determine all covered health 
care services and categorize the depression diagnosis corresponding to each Medicare 
beneficiary who had died from cancer. The Yale Human Investigation Committee determined 
that this research study did not directly involve human subjects. 
 
Patients 
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We identified elderly Medicare fee-for-service decedents who had breast, prostate, lung, 
colorectal, pancreatic, liver, kidney, melanoma, or hematological cancer diagnosed during 2004-
2011 and who died within 3 years of cancer diagnosis by December 2011 as a result of it. 
Because Medicare claims were used to identify patients with a pre-cancer diagnosis of 
depression in the year before cancer diagnosis, the study population was restricted to patients 
who were 66 years or older at cancer diagnosis and who were continuously enrolled in Medicare 
Parts A and B for at least 12 months before cancer diagnosis through death. This provides a 
minimum of 12 months of Medicare claims data to ascertain depression. Patients were excluded 
from our analyses if their cancer diagnosis occurred solely according to death certificates or 
autopsy claims, if they lived less than 6 months after cancer diagnosis, or if their income or 
education by zip code information was unknown. 
 
Key dependent variables 
Outcomes of interest examined include 6 EOL care intensity measures developed by 
Earle et al.: >1 hospitalization within 30 days of death, >1 emergency department (ED) visit 
within 30 days of death, ≥1 intensive care unit (ICU) admission within 30 days of death, in-
hospital death, any hospice use within 180 days of death, and chemotherapy received within 14 
days of death.26, 27 These data were gathered from Medicare claims. 
 
Key independent variable 
The primary independent variable examined in this study was depression. We identified 
the presence of depression among participants based on a search for depression diagnoses in all 
inpatient and outpatient Medicare claims data according to International Classification of 
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Diseases (ICD)-9 diagnostic codes 296.2, 296.3, 296.5, 296.6, 296.7, 298.0, 301.10, 301.12, 
301.13, 309.0, 309.1 and 311.3 These depression diagnoses looked at primary and secondary 
codes for major depressive disorder, bipolar disorder, affective personality disorder, and other 
medically relevant depressive symptoms; previous studies on depression and cancer have 
examined this set of ICD-9 codes.3, 22, 24 Patients are identified as having a diagnosis of 
depression if they had at least one claim with at least one of the ICD-9 codes.28 The timeframe 
for a pre-cancer depression diagnosis includes 12 months of Medicare claims that cancer 
decedents have upon enrollment at age 65. We thus categorized pre-cancer depression as 
occurring at any point during the 12-month period prior to cancer diagnosis, where individuals 
with pre-cancer depression can be either with or without post-cancer depression. Individuals with 
post-cancer depression are categorized as only having depression during the 6-month period after 
cancer diagnosis. Individuals with no depression at all do not have Medicare claims with the 
designated ICD-9 depression codes prior to or after their cancer diagnosis. 
 
Other covariates 
Baseline patient characteristics included race, age, gender, marital status, metropolitan 
status of residence, comorbidity, and disability status. The SEER-Medicare database also allows 
for census-based estimates of the median household income and the percentage of adults with a 
high school education or less at the zip code level. We used modified Charlson comorbidity 
conditions created for Medicare claims data to determine the degree of comorbidity per 
participant.29 This adaptation is based on an approach that requires the diagnostic code appear on 
either inpatient or outpatient Medicare claims data in the year prior to the cancer diagnosis; 
depression was excluded from the Charlson comorbidity index analysis because it is our 
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exposure variable of interest.22, 24, 30 Patients were categorized as having 0, 1 to 2, or more than 3 
comorbidities. A disability index, which serves as a multivariate claim-based indicator for 
services commonly needed by older patients with poor or functional performance, was also 
added.31 Tumor characteristics included tumor site, advanced stage of cancer (yes or no), 
multiple cancers (yes or no), and duration between cancer diagnosis and death (6 months-1 year, 
1-2 years, 2-3 years), as reported by the SEER cancer registries.  
 
Statistical analysis 
 Sociodemographic and tumor characteristics participants were summarized using mean 
(SD) for continuous variables and percentages for categorical variables. We used t-tests to 
compare the continuous age variable and Pearson chi-square tests to compare categorical patient 
sociodemographic and tumor characteristics between the different depression groups. 
Associations were observed between decedents with pre-cancer depression and those without 
depression, and between decedents with post-cancer depression and those without depression. To 
examine the unadjusted associations between depression diagnosis and our EOL care intensity 
outcomes of interest, we carried out additional Pearson chi-square tests. 
In multivariate analyses, we constructed 2-level hierarchical generalized linear models 
(HGLMs), clustering patients by hospital referral region (HRR), to investigate whether pre- or 
post-cancer depression compared to no depression might significantly account for the variation 
in EOL care intensity among cancer decedents. The conservative results provided by HGLMs 
were used to examine the adjusted associations between depression and EOL care intensity. 
Adjusted odds ratios (AOR) and 95% confidence intervals (CI) were estimated after adjustment 
for possible confounding variables such as patient demographics, clinical factors, and market 
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factors. In addition, we tested to see whether there are statistically significant interactions of 
depression with cancer type, race, and income on EOL care intensity. For all analyses, the 
reference group is comprised of participants with cancer but no depression either prior to or after 
cancer diagnosis in the timeframes previously mentioned. Statistical significance was set at 
p<0.05. All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC). 
 
Results 
Description of the study sample 
The sample consisted of 84,947 elderly Medicare beneficiaries reported with cancer 
during 2004-2011. 5,072 patients (6.0%) had pre-cancer depression whereas 6,677 patients 
(7.9%) had post-cancer depression. Bivariate associations of patient characteristics with either 
pre- or post-cancer depression to the reference group with no depression are shown in Table 1. 
The mean age of participants without depression was lower than that of participants with pre-
cancer depression (78.3 vs. 78.6, p<0.05), but higher than that of participants with post-cancer 
depression (78.3 vs. 77.8, p<0.001). In comparison to participants with no depression, those with 
either pre- or post-cancer depression were significantly more likely to be non-Hispanic white, 
male, and unmarried (p<0.001 for all). Participants with pre- or post-cancer depression also 
tended to have more comorbidities and a worse disability index than those without depression 
(p<0.001). However, decedents with pre- or post-cancer depression were significantly less likely 
to have multiple cancers than those without depression (p<0.001). When examining the months 
alive since cancer diagnosis, there were significantly lower percentages of participants with pre- 
or post-cancer depression compared to those without depression in the 1-2 years and 2-3 years 
categories (p<0.001 for all). 
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Depression and unadjusted differences in EOL care patterns 
Unadjusted associations between depression diagnosis and care intensity within our 
sample of cancer decedents are displayed in Figure 1. Participants with pre- or post-cancer 
depression were significantly less likely to receive ICU services in the last 30 days or late 
chemotherapy in the last 14 days of life than participants without depression (p<0.001 for both). 
Participants with pre- or post-cancer depression were also significantly less likely to experience 
in-hospital death than those without depression (p<0.001 for decedents with pre-cancer 
depression, p=0.001 for decedents with post-cancer depression). Participants with pre- or post-
cancer depression appear to have lower rates of repeat ED visits (p<0.05 for decedents with pre-
cancer depression, p=0.215 for decedents with post-cancer depression) and were significantly 
more likely to use hospice care in the last 180 days of life than their non-depressed counterparts 
(p<0.001). Patients with pre-cancer depression were less likely to have repeat hospitalizations 
(p=0.126) whereas patients with post-cancer depression were more likely to have repeat 
hospitalizations than their non-depressed counterparts (p=0.074); however, these results were 
statistically insignificant. 
 
Adjusted associations between depression and EOL care patterns 
The results of multivariate analyses from AORs and 95% CIs of pre- or post-cancer 
depression on EOL care intensity indicators are summarized in Table 2. As predicted, pre-cancer 
depression and post-cancer depression were associated with significantly lower rates of ICU use, 
in-hospital death, and late chemotherapy. Compared to decedents without depression, decedents 
with pre-cancer depression were significantly less likely to have repeated hospitalizations (AOR 
= 0.91, 95% CI = 0.83-0.99) or ED visits (AOR = 0.89, 95% CI = 0.83-0.94), experience in-
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hospital death (AOR = 0.83, 95% CI=0.77-0.89), and receive ICU services (AOR = 0.86, 95% 
CI = 0.79-0.93) or late chemotherapy (AOR=0.83, 95% CI=0.70-0.99). However, decedents with 
pre-cancer depression were more likely to use hospice care than decedents without depression 
(AOR = 1.20, 95% CI = 1.12-1.28). Participants with post-cancer depression had similar EOL 
care intensity patterns to those with pre-cancer depression, but were insignificantly more likely 
to have repeat hospitalizations than their counterparts without depression (AOR = 1.04, 95% CI 
= 0.97-1.12). In addition, we did not find significant interactions of depression with cancer type, 
race, and income on EOL cancer care intensity (p>0.05). 
 
Discussion 
 We determined the associations between depression and EOL care intensity among 
Medicare fee-for-service beneficiaries who died as a result of cancer. Our findings indicate that 
across various EOL care intensity indicators, participants with pre- or post-cancer depression 
tended to receive less aggressive EOL cancer care and were more likely to utilize hospice care 
compared to those without depression. These results are consistent with earlier studies that 
established depression is correlated with lower odds of receiving definitive treatment among 
cancer patients.3, 22  
Our findings build upon previous work in important ways. First, our research links 
depression, be it a pre- or post-cancer diagnosis of depression, with EOL cancer care 
aggressiveness over a longitudinal period of time. There have been no studies conducted to our 
knowledge that examined both pre- and post-cancer depression within the same study 
population. Previous research studies have investigated EOL cancer care patterns and 
expenditures either with pre-cancer depression alone or post-cancer depression alone, but those 
 Doan 14
findings were inconsistent. We did not find existing definitive conclusions about the associations 
of EOL care aggressiveness or quality for elderly participants with cancer and co-occurring 
depression. Our findings therefore provide a comprehensive view of EOL cancer care intensity 
patterns and depression among cancer decedents, whether they have pre-cancer depression, post-
cancer depression, or no depression at all. 
Secondly, instead of concentrating on a single cancer type, our research incorporates a 
broader range of cancer types than other studies, offering an all-inclusive understanding of the 
effects of depression on older patients with terminal cancer. Our study is strengthened by the 
large sample size and is adequately powered to detect statistically significant differences between 
depressed (prior to or after cancer diagnosis) and non-depressed cancer patients. We accordingly 
evaluated common terminal cancers among elderly adults, including breast, prostate, lung, 
colorectal, pancreatic, liver, kidney, melanoma, and hematological cancer. However, our results 
differ from previous studies that demonstrated associations between depression and greater EOL 
care aggressiveness with higher health care utilization.16, 23 These differences are plausible given 
that the onset of depression may vary by age, gender, or cancer type. Different types of cancer 
have distinct prevalence rates of depression, which may influence EOL care intensity. For 
example, the prevalence of depression was reported as 38% in pancreatic cancer patients, 14% to 
40% in breast cancer patients, and 4.7% to 33% in lung cancer patients.16 However, we did not 
find significant interactions between depression and cancer type, which suggests the robustness 
of our results. It is important that future research continue being conducted for specific types of 
cancer, depending on health priorities. Certain cancers may also lend themselves to different 
pathways and symptoms that could contribute to varying health care utilization trends. We 
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recommend that further understanding of the social or biological mechanisms that lead to these 
care patterns may enhance EOL care quality for all cancer patients.  
Third, while our research identifies significant differences in EOL care intensity patterns 
between participants with pre- or post-cancer depression and those with no depression, we did 
not find statistically important interactions between depression and race or income. In our 
population-based study, pre- or post-cancer depression was a significant predictor of care 
intensity in participants. Even after controlling for characteristics such as income, a proxy for 
socioeconomic mobility and access to care, the associations remained significant. We have 
reason to believe that patient preferences may play a role in these EOL care patterns. In a study 
looking at the effects of pre-cancer depression on older women with breast cancer, researchers 
arrived at two possible hypotheses for the increased mortality patterns among depressed 
participants – depression causes the individual to be less capable of functioning properly in 
society and may also be an indicator of global brain dysfunction.22 It is plausible that because the 
depressed cancer patient is less likely to seek care when ill or to adhere to medical regimens and 
treatments, these factors may contribute to lower rates of survival and health care utilization.22 
Patients who are diagnosed with depression and their providers may adopt a nihilistic attitude 
toward their illness, either due to depression or other negative aspects of their life, and thus 
would be unlikely to seek specialized care.3, 22, 32 Patients with a pre- or post-cancer diagnosis of 
depression may also prefer a quality-enhancing approach that incorporates palliative care options 
like hospice. In contrast, aggressive EOL care in patients without depression may be consistent 
with patient preferences for a life-prolonging approach. 
 There were several limitations to our study. First, we acknowledge that accurate 
diagnosis of patients with depression is frequently underreported in administrative claims data.33 
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However, the rate of depression in our study sample (13.9%) falls within the established 
prevalence range of 5% to 20% for cancer patients diagnosed major depressive disorder and 
depressive symptoms comorbid with cancer,10 supporting our findings. Because analyses are 
based on the SEER-Medicare fee-for-service beneficiary population, our findings include a 
considerable number of cases but may not necessarily characterize all Medicare beneficiaries in 
the United States. In addition to limited generalizability, we did not include patient preferences 
in our analyses because they are not known from Medicare claims data. While patient wishes 
have not been demonstrated to be a significant factor in expenditure variation at the end of life,20 
we believe physician behaviors may be a driving factor in the associations we observed between 
depression and EOL cancer care intensity. Future research examining patient experiences and 
physician practice behaviors with the associations between depression and EOL care intensity is 
needed. Finally, our retrospective study design may also limit our findings. Our population-based 
cohort is comprised of retrospective cancer decedents. Participants who had pre- or post-cancer 
depression but did not die during the window of time we chose would not be included in our 
analyses. Prospective research to confirm our retrospective research findings is therefore 
necessary.  
In conclusion, our study demonstrates that pre-cancer depression and post-cancer 
depression are associated with lower EOL cancer care intensity and higher overall hospice care 
utilization among elderly patients with cancer. While the significantly higher rates of hospice 
care among participants with pre- or post-cancer depression are promising, our findings on less 
aggressive EOL care patterns among depressed patients should be interpreted with caution. 
Improving physician awareness of the high prevalence of depression comorbid with cancer and 
accurate screening and treatment for depressed patients can lessen the detrimental influence of 
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depression on health outcomes in cancer.3 Earlier communication and initiation of hospice for all 
patients can also help increase palliative care rates. More discussions among medical providers 
on cancer and co-occurring mental illness can lead to improved protocols for depressed patients 
who need appropriate mental health treatment and end-of-life care, especially among this elderly 
cancer patient population. Such actions can potentially lower unnecessary utilization of health 
care resources among elderly adults with cancer and promote better, more empathetic care that 
aligns with patient preferences. 
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Table 1. Selected patient characteristics, by depression diagnosis 
 No 
Depression 
Pre-Cancer 
Depression 
P-Value* Post-Cancer 
Depression 
P-Value* 
 N=73,198 N=5,072  N=6,677  
Race (%)   <0.001  <0.001 
     Non-Hispanic White 82.4 86.2  86.3  
     African American 8.4 6.5  6.5  
     Hispanic 4.5 5.0  4.6  
     Asian 4.8 2.4  2.6  
Age in years (mean, SD) 78.3 (6.7) 78.6 (7.0) 0.002 77.8 (6.7) <0.001 
Female (%)   <0.001  <0.001 
     No 45.5 64.4  57.6  
     Yes 54.5 35.6  42.4  
Marital Status (%)   <0.001  <0.001 
     Married 52.7 38.5  45.7  
     Unmarried 42.4 56.2  49.7  
     Unknown 4.9 5.3  4.6  
Metropolitan (%)   0.006  0.431 
     Metro 82.3 80.8  82.7  
     Non-metro/Unknown 17.7 19.2  17.3  
Income (%)   <0.001  0.071 
     < $33,000 23.1 24.2  22.2  
     $33,000 - $39,999 15.8 17.2  15.4  
     $40,000 - $49,999 20.4 21.0  20.2  
     $50,000 - $62,999 19.2 18.4  19.3  
     ≥ $63,000 21.5 19.2  22.9  
High School Education (%)   0.378  0.774 
    < 30% 21.3 20.3  21.2  
     30% - 39% 15.5 15.4  15.9  
     40% - 49% 17.3 18.1  17.7  
     50% - 59% 18.7 19.1  18.4  
     ≥ 60% 27.2 27.1  26.9  
Comorbidity (%)   <0.001  <0.001 
     None 46.9 24.1  42.2  
     1 to 2 38.5 43.0  40.9  
     More than 3 14.7 32.9  16.9  
Disability Status (%)   <0.001  <0.001 
     No 92.5 70.8  87.1  
     Yes 7.5 29.2  12.9  
Tumor Site (%)   <0.001  <0.001 
     Breast 7.4 10.6  7.5  
     Prostate 7.8 4.3  4.4  
     Lung 40.4 41.7  40.4  
     Colorectal 14.5 14.5  17.5  
     Pancreas 7.0 6.3  8.8  
     Liver 2.7 2.3  1.8  
     Kidney 3.3 3.1  3.0  
     Skin 4.3 4.0  2.1  
     Hematological cancer 12.6 13.1  14.6  
Stage IV at diagnosis (%)   <0.001  0.625 
     Not stage IV 69.1 74.2  68.8  
     Stage IV 30.9 25.8  31.2  
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Multiple cancers (%)   <0.001  <0.001 
     No 87.1 89.4  89.8  
     Yes 12.9 10.6  10.2  
Duration between cancer 
diagnosis and death (%) 
  <0.001  <0.001 
     6 months - 1 year 36.8 41.6  47.0  
     1 - 2 years 41.0 40.0  36.7  
     2 - 3 years 22.1 18.4  16.4  
*: No depression as reference. 
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Figure 1. Differences in end-of-life care patterns, by depression diagnosis* 
 
*: 95% confidence intervals are provided for each care intensity indicator, by depression diagnosis. 
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Table 2. Adjusted associations between depression diagnosis and EOL care patterns 
 No Depression Pre-Cancer Depression Post-Cancer Depression 
 N=73,198 N=5,072 N=6,677 
Repeat hospitalizations    
Adjusted odds ratio (95% CI)* Reference 0.91 (0.83, 0.99) 1.04 (0.97, 1.12) 
Repeat ED visits    
Adjusted odds ratio (95% CI)* Reference 0.89 (0.83, 0.94) 0.96 (0.91, 1.01) 
ICU use    
Adjusted odds ratio (95% CI)* Reference 0.86 (0.79, 0.93) 0.84 (0.79, 0.91) 
In-hospital death    
Adjusted odds ratio (95% CI)* Reference 0.83 (0.77, 0.89) 0.89 (0.84, 0.95) 
Any hospice use    
Adjusted odds ratio (95% CI)* Reference 1.20 (1.12, 1.28) 1.15 (1.08, 1.22) 
Late chemotherapy    
Adjusted odds ratio (95% CI)* Reference 0.83 (0.70, 0.99) 0.70 (0.61, 0.82) 
*: All data are adjusted for patient demographics, clinical factors, and market factors, using 2-
level hierarchical generalized linear models and clustering patients by hospital referral region. 
Bold indicates p<0.05. 
 
 
